新冠疫苗项目重大调整是否改变接种意愿?一项定性调查
2021年2月至4月,在澳大利亚珀斯对28名成人进行定性访谈,评估2021年4月8日澳大利亚免疫技术咨询小组(ATAGI)将辉瑞-BioNTech疫苗定为50岁以下成人首选疫苗前后新冠疫苗接种意愿的变化。结果显示,50岁以下18人中14人接种意愿不变,4人更加担忧;50岁及以上10人中8人意愿不变,2人更加谨慎。主要担忧从疫苗效力差异转向安全性。
要点
- 项目调整后,多数参与者接种意愿保持不变,部分变得更加担忧或谨慎。
- 调整前主要担忧疫苗效力不同,调整后转为安全性。
- 作者认为政府、医疗服务提供者和媒体需更好解决疫苗担忧。
核心结论
- 大多数参与者为「谨慎接受者」并打算接种疫苗,许多人在项目调整前后均持有此意愿。
- 澳大利亚政府、医疗服务提供者和媒体需要更好地解决新冠疫苗担忧,以帮助有接种意愿者获得疫苗。
研究设计与样本
- 定性访谈研究,于2021年2月至4月在澳大利亚珀斯对28名成人进行项目调整前后的访谈。
- 使用新冠疫苗接种意愿模型,将参与者分类为接受者、谨慎接受者、等待者和拒绝者。
主要发现
- 调整前,50岁以下18人中7人为接受者,10人为谨慎接受者,1人为等待者。
- 调整后,50岁以下18人中14人接种意愿不变,4人更加担忧。
- 调整前,50岁及以上10人中5人为接受者,5人为谨慎接受者;调整后8人意愿不变,2人更加谨慎。
- 调整前主要担忧疫苗效力不同,调整后担忧转向安全性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the "preferred" vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions. METHOD: We undertook qualitative interviews from February - April 2021 before and after the program change with 28 adults in Perth, Western Australia. Using our COVID-19 vaccine intentions model, we assessed changes in participants' COVID-19 vaccine intention before and after the program change. Participants were classified as 1) 'acceptors': no concerns about COVID-19 vaccine safety, efficacy, access and would accept whatever vaccine is offered, 2) 'cautious acceptors': some concerns and would prefer a particular vaccine brand but would accept whatever is offered, 3) 'Wait awhile': for more data, easier access, for another vaccine brand, a greater perceived COVID-19 threat or until mandatory, or 4) 'refuser': no intention to vaccinate due to concerns about safety and/or efficacy. RESULTS: Before the change, 7/18 of those aged < 50 years were 'acceptors,' 10/18 were 'cautious acceptors' and 1/18 was 'wait awhile.' Overall, 14/18 participants had the same COVID-19 vaccine intention after the change; 4/18 became more concerned. For those aged ≥ 50 years and before the change, 5/10 were 'acceptors' and 5/10 were 'cautious acceptors.' After the change, 8/10 still had the same COVID-19 vaccine intention; 2/10 became more cautious. The major concern before the program change was COVID-19 vaccines having different vaccine efficacy; the concern pivoted to safety. CONCLUSION: The majority of participants were 'cautious acceptors' who intended on being vaccinated; many had this intention before and after the program change. The Australian government, health care providers and media need to better address COVID-19 vaccine concerns to assist those with COVID-19 vaccine intentions receive a vaccine.
引用
- Carlson SJ, McKenzie L, Roberts L, et al. Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation. Vaccine. 2021. PMID: 34952758. doi:10.1016/j.vaccine.2021.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。